Orvis
16 years ago
Lumera Reports Second Quarter 2008 Results, Confirms Progress on Proposed Merger
Monday August 4, 4:30 pm ET
BOTHELL, Wash.--(BUSINESS WIRE)--Lumera Corporation (NASDAQ:LMRA - News), a leader in photonics communication, today reported financial results for the second quarter 2008.
ADVERTISEMENT
Revenues totaled $1,499,000 for the three months that ended June 30, 2008 compared to $934,000 for the same period in 2007, reflecting an increase of 60%. Lumera’s loss from continuing operations totaled $1,649,000 or $0.08 per share for the second quarter of 2008 compared with a loss from continuing operations of $2,188,000 or $0.11 per share for the same period in 2007.
Revenues totaled $1,983,000 for the six months ended June 30, 2008 compared to $1,794,000 for the same period in 2007, reflecting an increase of 11%. Lumera’s loss from continuing operations totaled $5,226,000 or $0.26 per share for the six months of 2008 compared with a loss from continuing operations of $3,909,000 or $0.19 per share for the same period in 2007.
“We are pleased with our results this quarter," said Dr. Joe Vallner, Interim Chief Executive Officer of Lumera. “We have the highest level of government contract revenue commitments in our history which, as expected, will drive increasing contract revenues for us this year. Achieving our Telcordia testing milestones validates for us that our materials and devices can meet tough industry standards. Our restructuring efforts are bearing fruit, allowing us to focus singularly on our electro-optic business opportunities, and we’ve made good headway reducing embedded operating costs. We expect to see more of the same in the coming quarter leading up to our proposed merger.”
Lumera’s electro-optic business unit is developing a new generation of electro-optic modulators and other devices for optical networks and systems based on proprietary polymer materials.
During the quarter, Lumera announced that it had successfully completed its Telcordia standard reliability testing of its packaged polymer-based electro-optic modulators. Achieving these positive test results for the modulators demonstrates the viability of Lumera’s electro-optic polymer technology for component fabrication and validates the assertion that polymer modulators can pass the same rigorous tests required of industry standard components. Lumera is now in a position to share its internal reliability test results with potential customers and business partners.
The company also recently announced that it had completed a device shipment to Lockheed Martin in conjunction with a third order placed under the Material Transfer Agreement signed with Lockheed Martin in the first quarter 2008. This recent shipment evidences that Lumera’s relationship with Lockheed is continuing and expanding beyond electro-optic materials into prototype devices.
Proposed Merger with GigOptix, LLC
On March 27, 2008, Lumera Corporation and GigOptix, LLC (“GigOptix”) announced their entry into a definitive agreement to merge the two companies. Upon completion of the merger, which is subject to Lumera shareholder and other regulatory approval, existing securities holders of Lumera and GigOptix will each own approximately 50% of the outstanding securities of a new holding company named “GigOptix, Inc.” which will trade on the NASDAQ Market under the ticker symbol “GIGX.”
Lumera also recently announced that the Company had entered into definitive agreements with selected institutional investors to sell 4 million shares of its common stock and warrants to purchase an additional 2 million shares through a registered direct offering for net proceeds of approximately $2.8 million, after deducting offering fees and expenses. With the net proceeds from this offering, which was completed on July 16, 2008, we have met the minimum capital requirements closing condition in the GigOptix merger agreement.
Activities associated with our proposed merger with GigOptix continue to progress, albeit on a delayed schedule, due to a longer than expected period to produce audited GAAP financial statements at GigOptix. Information pertaining to the proposed merger, audited historical results for GigOptix LLC, and pro forma financial statements of the combined businesses will become available when an initial Registration Statement on Form S-4 is filed with the SEC. Due to the time required to produce the GigOptix financial statements, we currently expect to file the S-4 prior to the end of the third quarter. At that time, we anticipate holding a joint conference call to introduce Dr. Avi Katz and to discuss the proposed merger with GigOptix.
shmoopy38
17 years ago
Lumera Reports First Quarter 2007 Results and Updates on Product Development Progress
BOTHELL, Wash., May 03, 2007 (BUSINESS WIRE) -- Lumera Corporation (NASDAQ: LMRA), a leader in the emerging field of nanotechnology, today reported financial results for the first quarter 2007 and released information regarding its current product development progress.
Revenues totaled $860,000 for the three months ended March 31, 2007 compared with $503,000 for the same period in 2006, a 71 percent increase over the prior year. Lumera's net loss totaled $2,696,000 or $0.13 per share for the three months ended March 31, 2007 compared with $3,120,000 or $0.19 per share for the same period in 2006.
"Lumera's first quarter is an indication of our continued progress forward," said Lumera Chief Executive Officer Tom Mino. "Increased revenue from government contracts resulted in the improved financial performance from a year ago. We've also entered into agreements in both business units that will enable us to continue building on our progress."
Summary Discussion of Product Development
Lumera develops proprietary polymer materials which are used in bioscience products and in electro-optic devices further detailed in the market summaries below.
Bioscience
Lumera is developing label free high throughput methods targeted at the biological and medical research markets.
Early in the quarter, Lumera announced that Dr. Josh LaBaer of the Harvard Institute of Proteomics presented his early research results using the ProteomicProcessor(TM) at the PEPTalk meeting in San Diego. Dr. LaBaer reported the successful integration of Harvard's NAPPA protein array methodology on Lumera's chip surface and, together, Lumera and Dr. LaBaer's group are working on building an array of kinase proteins.
Also during the quarter, the Company announced an important application for its ProteomicProcessor(TM) developed by the Institute for Systems Biology. The application allowed researchers to identify a novel biomarker panel associated with liver toxicity in mice. This development potentially opens a new avenue demonstrating how the instrument could be used in biomarker discovery.
Electro-Optics
Lumera is developing a new generation of electro-optic modulators and other devices for optical networks and systems based on proprietary polymer materials.
During the quarter, the Company announced it had received a purchase order from Lockheed Martin and entered into an agreement with Lockheed for Lumera's high electro-optic activity materials. The term of the agreement ends December 31, 2007, at which time Lockheed Martin will advise Lumera of its intentions regarding a commercial license for the materials.
Also during the quarter, Lumera announced that it had been awarded an extension to a U.S. government contract to continue development of technologically advanced wideband optical modulators. The twelve month contract is valued at approximately $1.15 million. The overall contract value has now reached approximately $6.9 million.
Summary Financial Discussion
Revenues totaled $860,000 for the three months ended March 31, 2007 compared with $503,000 for the same period in 2006, a 71 percent increase over the prior year. Government contract revenue totaled $775,000 for the current quarter, in increase of $292,000 from $483,000 in 2006 due primarily to higher billings on two of our contracts.
Product revenues totaled $85,000 for the current quarter, reflecting sales of electro-optic modulators. Backlog on our government contracts totaled $2,048,000 at March 31, 2007.
Operating expenses for the three months ended March 31, 2007, decreased by $139,000 to $3,434,000 compared to $3,573,000 for the same period in 2006. Research and Development expense, which totaled $1,271,000 for the three months ended March 31, 2007, decreased by $307,000, or 19 percent, from $1,578,000 for the same period in 2006 due to increased government contract activities resulting in higher levels of labor and related overhead costs being allocated to the cost of contract revenues and lower depreciation costs as our asset base becomes more fully depreciated. Marketing, general and administrative expense, which totaled $2,163,000 for the three months ended March 31, 2007, increased by $168,000, or 8 percent, from the same period in 2006 due primarily to cash compensation costs associated with additional sales and marketing and administrative personnel and increased consulting fees.
Lumera's net loss totaled $2,696,000 or $0.13 per share for the three months ended March 31, 2007, compared with $3,120,000, or $0.19 per share for the same period in 2006.
Lumera, which ended the quarter with $24.1 million in cash and investment securities, used $2.2 million in cash to fund operations and working capital requirements during the three months ended March 31, 2007, a decrease of $605,000 over the same period in 2006. Capital expenditures, which include leasehold and related capital improvements, totaled $71,000 for the first quarter of 2007, down from $317,000 during the same period in 2006.
Conference Call
Lumera will host a conference call to discuss its third quarter of 2006 financial results on Thursday, May 3 at 4:30 p.m. EDT. The call will be broadcast over the Internet and can be accessed from the company's web site at www.lumera.com. Additionally, U.S. participants may join the conference call by dialing 800.638.4817 ten minutes prior to the start of the conference. International participants can dial 617.614.3943. The conference passcode number is 23714654. A telephone replay of the call will be available through May 10, and can be accessed by dialing 888-286-8010 (for U.S. participants) or 617-801-6888 (for international participants). The replay passcode is 32065724. A replay of the conference call will be available on the company's web site.
About Lumera
Lumera is a leader in the emerging field of nanotechnology. The company designs proprietary molecular structures and polymer compounds for the bioscience and communications industries, both of which represent large market opportunities. The company also has developed proprietary processes for fabricating such devices. For more information, please visit www.lumera.com.
Certain statements contained in this release are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and to develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products; and other risk factors identified from time to time in the company's SEC reports, including its Annual Report on Form 10-K, and its Quarterly Reports on Form 10-Q.
Lumera Corporation
Condensed Balance Sheets
(In thousands)
(Unaudited)
March 31, December 31,
Assets 2007 2006
------------ -------------
Current assets
Cash and cash equivalents $ 5,443 $ 10,521
Investment securities, available-for-
sale 18,659 15,788
Accounts Receivable, net of allowance 5 380
Costs and estimated earnings in excess
of billings on uncompleted contracts 380 338
Other current assets 462 600
------------ -------------
Total current assets 24,949 27,627
Property and equipment, net 2,612 2,759
Restricted Investments 700 700
Other Assets 46 46
------------ -------------
Total assets $ 28,307 $ 31,132
============ =============
Liabilities and Shareholders' equity
Current liabilities
Accounts payable $ 398 $ 850
Accrued liabilities 891 982
------------ -------------
Total current liabilities 1,289 1,832
Deferred rent, net of current portion 385 407
------------ -------------
Total current liabilities 1,674 2,239
Commitments and contingencies
Shareholders' equity
Common stock at par value 20 20
Additional paid-in capital 90,125 89,690
Accumulated other comprehensive loss 2 1
Accumulated deficit (63,514) (60,818)
------------ -------------
Total shareholders' equity 26,633 28,893
------------ -------------
Total liabilities and shareholders' equity $ 28,307 $ 31,132
============ =============
Statements of Operations
(In thousands, except earnings per share and share data)
(Unaudited)
Three months ended March 31,
----------------------------
2007 2006
-------------- -------------
Revenue $ 860 $ 503
Cost of revenue 443 258
-------------- -------------
Gross profit 417 245
-------------- -------------
Research and development expense 1,271 1,578
Marketing, general and administrative
expense 2,163 1,995
-------------- -------------
Total operating expenses 3,434 3,573
-------------- -------------
Loss from operations (3,017) (3,328)
Interest income 321 208
-------------- -------------
Net loss from operations $ (2,696) $ (3,120)
============== =============
Net loss per share-basic and diluted $ (0.13) $ (0.19)
============== =============
Weighted-average shares outstanding -
basic and diluted 20,055,352 16,757,005
============== =============
SOURCE: Lumera Corporation
Lumera Corporation
Helene F. Jaillet, 425-398-6546 (Investor Relations)
or
The Summit Group Communications
Todd Wolfenbarger, 801-595-1155 (Media)
801-244-9600 cell
shmoopy38
17 years ago
Los Alamos National Laboratory Completes Successful Analysis of Antibodies Using Lumera Corporation Technology
8:45 AM EST November 15, 2006
Lumera Corporation (Nasdaq:LMRA), an emerging leader in the field of nanotechnology, announced today that its proprietary Heterodimer Protein Technology (HPT) and ProteomicProcessor(TM) were both successfully used to analyze single chain antibodies from Los Alamos National Laboratory (LANL).
"Lumera is pleased to work with Los Alamos National Laboratory," said Tom Mino, Lumera CEO. "Our Bioscience Business Unit channels our nanotechnology platform into developing useful tools for finding and speeding up the delivery of the next billion-dollar therapeutic drug. This work illustrates the versatility of the Lumera antibody discovery products, which we plan to offer next year to the drug discovery market."
"Currently, we are using e-coil tagged, single chain antibodies in a high throughput flow cytometry-based screening and characterization," said Peter Pavlik, project leader at Los Alamos. "Having access to Lumera's high throughput SPR-based characterization technology that uses the same coil chemistry would increase our ability to characterize antibodies in great detail."
"The extraordinary revenue growth rate of therapeutic antibodies is one of the most attractive in the pharmaceutical industry," said Ronald Dudek, Director of Business Development at Lumera Corporation. "The Lumera antibody discovery products will be the first of a suite of new products that present a total solution to our partners in the drug discovery market. We believe that applied nanotechnology solutions, like those we will offer, will increase the speed and efficiency of pharmaceutical drug discovery."
Los Alamos National Laboratory is a world leader in phage display technology, antibody engineering, and the development of high throughput screening assays. Phage display is an emerging technology for the production of very large and highly diverse antibody libraries. Antibodies are the human body's immune response to infection, which is typically caused by foreign substances or antigens. Scientists have found that antibodies have the capacity to bind specifically to antigens, thereby neutralizing the antigen. This ability is giving rise to a very large pharmaceutical market known as therapeutic antibodies. Rituxan, a highly successful billion-dollar commercial drug which treats non-Hodgkin's lymphoma, is an example of a therapeutic antibody drug.
The LANL single chain antibodies were engineered to contain the Lumera E-Coil peptide tag. The engineered antibodies were then screened using the Lumera NanoCapture(TM) K-Coil microarray slide and ProteomicProcessor(TM) instrument system.
About Lumera
Lumera is a leader in the emerging field of nanotechnology. The company designs proprietary molecular structures and polymer compounds for the bioscience and communications/computing industries, both of which represent large market opportunities. The company also has developed proprietary processes for fabricating such devices. For more information, please visit www.lumera.com.
About Los Alamos National Laboratory
Los Alamos National Laboratory is a multidisciplinary research institution engaged in strategic science on behalf of national security. The Laboratory is operated by a team composed of Bechtel National, the University of California, BWX Technologies, and Washington Group International for the Department of Energy's National Nuclear Security Administration. Los Alamos enhances national security by ensuring the safety and reliability of the U.S. nuclear stockpile, developing technologies to reduce threats from weapons of mass destruction, and solving problems related to energy, environment, infrastructure, health and global security concerns.
Certain statements contained in this release are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and to develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products; and other risk factors identified from time to time in the company's SEC reports, including its Annual Report on Form 10-K, and its Quarterly Reports on Form 10-Q.
SOURCE: Lumera Corporation
The Summit Group Communications Todd Wolfenbarger, 801-595-1155; 801-244-9600 (cell)
shmoopy38
17 years ago
Lighting up Nanotechnology
Published in M2 PressWIRE on Tuesday, 31 October 2006 at 16:21 GMT
Copyright (C) 2006, M2 Communications Ltd.
Lumera (NASDAQ:LMRA) lights the way in the development of polymer materials and products based on those materials for use in wireless and optical communications networks and in biochemical analysis. Lumera develops custom electro-optic devices for the US government, particularly the Department of Defense, which accounts for nearly all of sales. Products in development include compact panel wireless antennas (AccuPath), disposable biochips used to isolate DNA and protein samples for testing (NanoCapture), and electro-optic modulators and optical interconnects for use in telecommunications applications.
Shares were up 13% since Harvard Medical School researchers started using Lumera's ProteomicProcessor Biosensor.
Bellwether Report is tracking Lumera Corp. for more information on the company, sign up to BellwetherReport.com for a complimentary subscription. To view the company press release continue below.
Lumera Corporation, an emerging leader in the field of nanotechnology, announced that Harvard Medical School researchers are now building next generation discovery and diagnostics methods with Lumera's ProteomicProcessor(TM) Biosensor.
During the past year, Lumera has placed four beta units with highly respected, world renowned research organizations to demonstrate and establish new applications that take advantage of the instrument's unprecedented throughput in a label-free format. Harvard has served as a beta site for Lumera's biosensor platform, the ProteomicProcessor(TM), since mid-2006. The Harvard collaboration is focused on integrating their NAPPA (Nucleic Acid Programmable Protein Array) technology, which provides a simple and cost-effective way to generate a protein biochip, with the ProteomicProcessor(TM) to read and analyze the biochip.
"In the past quarter, we have successfully narrowed the window of processing conditions to produce a ProteomicProcessor(TM) compatible NAPPA array," said Dr. Joshua LaBaer, Director of the Harvard Institute of Proteomics. "We now have a solid foundation on which to begin our development efforts. Among our first areas of investigation will be probing a family of 200 kinase proteins for their interaction with and among drug families relevant to cancer research." "There is a significant amount of value to the pharmaceutical development market in combining these two technologies," said Dr. Timothy Londergan, Director of Lumera's Bioscience Business. "This will ultimately lead to new products that take advantage of NAPPA's unique capability of producing proteins on demand and the ProteomicProcessor's unique ability to understand in great detail how the proteins are interacting with each other and with other compounds, like, for example, drug candidates. We are particularly interested in using NAPPA to generate a human protein kinase array, allowing us to address a very large and growing segment of the drug discovery market with a high value consumable product." According to Frost and Sullivan, the pharmaceutical industry spends nearly one third of its $50 billion of research and development dollars on kinase inhibitor therapeutics. Kinases are a class of proteins which are known to signal certain illnesses, including some cancers, to the "on" or diseased state. Kinase inhibitors effectively can turn the "on" signal to an "off" state. Interest in this area has been propelled by the success of Gleevec, a multibillion drug from Novartis which was the first approved drug to directly turn off the signal of a protein known to cause a cancer.
Bellwether Report is an online financial newsletter focused on researching small-cap and large-cap public companies. Information has been obtained from sources considered to be reliable, but we do not guarantee that it is accurate or complete. This material is not an offer to sell or a solicitation of an offer to buy any securities. BWR and its affiliates, officers, directors and agents have been compensated to perform research and therefore information should not be construed as unbiased. Each contract varies in duration, services performed and compensation received. BWR is not responsible for any claims made by the Company. You should independently investigate and fully understand all risks before investing. We are not a registered broker-dealer. Before investing in any securities, you should consult with your financial advisor and a registered broker-dealer. Our views and opinions regarding the Company are our own views and are based on information that we have received, which we assumed to be reliable. We do not guarantee that the Company will perform as we expect, and any comparisons we have made to other companies may not be valid or come into effect. Statements included may contain forward looking statements, including the Company's intentions, forecasts, plans or other matters that haven't yet occured. Such statements involve a number of risks and uncertainties. Further information on potential factors that may affect, delay or prevent such forward looking statements from coming to fruition can be found in their specific Financial reports, including the 10-K and 10-Q, which are filed with the Securities and Exchange Commission (SEC). Bellwether Report will receive 25% of all sales from the Bell Alerts services and will receive 66% of all sales of Research Reports.
Release date: 31 Oct 2006
shmoopy38
17 years ago
Update: Paulson Investment's 29th Annual Westergaard SmallCap Conference to Showcase Emerging Industry Leaders
Monday October 30, 2:25 pm ET
Hosted by Paulson Investment Company, Inc. and Dutton Associates, Event Scheduled for Monday, November 6, 2006 in New York City
NEW YORK, NY--(MARKET WIRE)--Oct 30, 2006 -- Paulson Investment Company, Inc., a wholly owned subsidiary of Paulson Capital Corp. ("Paulson") (NASDAQ:PLCC - News), and Dutton Associates today issued the following updates and finalized list of presenters for Paulson Investment's 29th Annual Westergaard SmallCap Conference.
The Conference will showcase small and emerging growth companies focused on establishing leadership in a broad range of industry sectors, including alternative energy, security, technology, pharmaceutical, biotechnology, environmental and consumer products. Founded in 1978 by noted small cap analyst John Westergaard, this conference provides a venue for select small cap companies to share detailed insight into their business operations, short and long term growth strategies, and industry vision.
Hundreds of investment professionals have already pre-registered to attend the one-day conference. Space is limited, so investment professionals interested in attending are encouraged to pre-register for the event. For more information or to pre-register, please visit www.westergaardsmallcap.com.
EVENT AT A GLANCE:
WHEN: Monday, November 6, 2006 from 8:00 A.M. to 5:30 P.M. ET
WHERE: Waldorf-Astoria Hotel
301 Park Avenue (Between 49th and 50th)
New York City
KEYNOTE
SPEAKER: Stephen Moore, senior economics writer for The Wall Street
Journal and economic commentator for CNBC TV. The author of four
books, including, most recently, "It's Getting Better All the
Time: The 100 Greatest Trends of the Last Century," Moore has
also served as a senior fellow in economics at the Cato
Institute, where he had published dozens of studies in federal
budget and tax policy. (Previously announced keynote speaker,
Lawrence Kudlow, will not be presenting, due to a conflict
related to reporting of the national elections.)
This year's conference will play host to companies scheduled to give multiple presentations throughout the day to small, informal groups of investment professionals. Confirmed presenting companies will include:
American Mold Guard, Inc. (NASDAQ:AMGI - News)
Ampex Corporation (NASDAQ:AMPX - News)
Ascent Solar Technologies, Inc. (NASDAQ:ASTI - News) (BSX: AKC)
AspenBio Pharma, Inc. (OTC BB:APNB.OB - News)
AVI BioPharma, Inc. (NASDAQ:AVII - News)
Baldwin Technology Co., Inc. (AMEX:BLD - News)
Charles & Colvard, Ltd. (NASDAQ:CTHR - News)
Chembio Diagnostic, Inc. (OTC BB:CEMI.OB - News)
Converted Organics, Inc. (Not Publicly Traded)
DayStar Technologies, Inc. (NASDAQ:DSTI - News)
DXP Enterprises, Inc. (NASDAQ:DXPE - News)
Elron Electronic Industries, Ltd. (NASDAQ:ELRN - News)
GigaBeam Corporation (NASDAQ:GGBM - News)
Green Plains Renewable Energy, Inc. (NASDAQ:GPRE - News)
Harbin Electric, Inc. (OTC BB:HRBN.OB - News)
ICOP Digital, Inc. (NASDAQ:ICOP - News) (NYSE Arca: ICOP)
INX, Inc. (NASDAQ:INXI - News)
Lumera Corporation (NASDAQ:LMRA - News)
Memry Corporation (AMEX:MRY - News)
MorphoSys AG (Frankfurt:MOR.F - News) (Prime Standard Segment, TecDAX)
Midway Gold Corp. (TSX VENTURE:MDW.V - News)
Nephros, Inc. (AMEX:NEP - News)
Neuralstem, Inc. (Not publicly traded)
Nymox Pharmaceutical Corporation (NASDAQ:NYMX - News)
QPC Lasers, Inc. (OTC BB:QPCI.OB - News)
Shumate Industries, Inc. (OTC BB:SHMT.OB - News)
Seabridge Gold, Inc. (AMEX:SA - News)
Taser International, Inc. (NASDAQ:TASR - News)
Universal Guardian Holdings, Inc. (OTC BB:UGHO.OB - News)
Vaughan Foods, Inc. (Not Publicly Traded)
To date, supporting corporate sponsors include:
Gold Level
Elite Financial Communications Group, LLC
RBC Dain Rauscher, Inc.
Silver Level
Capital IQ, Inc.
LANE PR
Research in Motion (BlackBerry)
Thomson Financial
ValueRich, Inc.
Vintage Filings, LLC
About Dutton Associates
Dutton Associates is one of the largest issuer-paid equity research firms in the United States and its investment performance is ranked comparable to that of the top Wall Street firms. Its analysts, primarily CFAs with over 20 years of experience at the major securities firms, are among the most experienced on Wall Street. The Company offers high-quality, independent, fundamental research on small cap public companies.
About Paulson Capital Corp.
Paulson Capital Corp. is the parent company to Paulson Investment Company, Inc. Located in Portland, Oregon, Paulson Investment Company, Inc. is the Northwest's largest independent brokerage firm and a national leader in public offerings of small and emerging growth companies with capital needs of $5 million to $45 million. Founded by Chet Paulson in 1970, it has managed or underwritten nearly 160 public and private offerings and has generated more than $1 billion for client companies.
Paulson Investment Company, Inc. was the managing underwriter for the initial and/or secondary public offerings for one or more of the companies affiliated with this conference. Paulson Investment Company, Inc. may make a market in one or more of the securities affiliated with this conference. These markets may, however, be changed at any time without notice. Individuals associated with Paulson Investment Company, Inc., and its officers and/or directors may hold shares in companies affiliated with this conference and may increase or decrease such holdings without notice. The contents of the presenting company's profiles on this site were prepared by Dutton Associates and are not to be construed as a solicitation to buy or sell any securities. Paulson Investment Company, Inc. does not warranty, guarantee or make any representations, or assume any liability with regard to financial results based on the use of information on this site.
This release may contain "forward-looking statements" based on current expectations but involving known and unknown risks and uncertainties. Actual results of achievements may be materially different from those expressed or implied. The Company's plan and objectives are based on judgments with respect to future conditions in the securities markets as well as general assumptions regarding the economy and competitive environment in the securities industry, which can be volatile and out of our control. In particular, we make assumptions about our ability to complete corporate finance transactions and increase the volume and size of our securities trading operations, which are difficult or impossible to predict accurately and often beyond the control of the Company. Therefore, there can be no assurance that any forward-looking statement will prove to be accurate.
Contact:
FOR MORE INFORMATION, PLEASE CONTACT:
Dodi Handy
President and CEO
Elite Financial Communications Group
407-585-1080
plcc@efcg.net
--------------------------------------------------------------------------------
Source: Paulson Capital Corp.
Level up your trading with our powerful tools and real-time insights all in one place.
Major_Bankz
18 years ago
Hot Features
Premium
